NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-08-11 18:45இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
₹30.37 Cr Revenue in Q1 FY27: TAKE Limited Returns to Profitability with Strategic Pivot
TAKE Limited reported a significant operational turnaround in Q1 FY27, with consolidated revenue reaching ₹30.37 Cr compared to nil revenue in the prior-year quarter. The company posted a net profit of ₹1.06 Cr, reversing a loss of ₹0.91 Cr in Q1 FY26. A critical factor in this recovery is the 99.62% reduction in finance costs to just ₹0.07 lakhs, reflecting a successful debt-elimination strategy. Additionally, the company announced a strategic entry into the longevity and biohacking market, aiming to leverage its clinical expertise in the preventive healthcare sector.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has successfully restarted its revenue engine after several quarters of near-zero activity and has virtually eliminated its interest-bearing debt.
ஏன் இது முக்கியம்The Q1 revenue of ₹30.37 Cr represents approximately 56% of the total TTM revenue (₹54 Cr), indicating a massive acceleration in business activity. The pivot to high-margin longevity products could structurally change the company's margin profile if successful.
Q1 FY27 Revenue: ₹30.37 கோடிQ1 FY27 Net Profit: ₹1.06 கோடிFinance Cost Reduction: 99.62%Q1 வருவாய் vs TTM வருவாய்: 56.2%சந்தை மதிப்பு: ₹341 கோடி
📅 குறுகிய காலம்The stock may see positive momentum as the market reacts to the sharp turnaround from losses to profitability and the clean, debt-free balance sheet.
📈 நீண்ட காலம்The long-term trajectory depends on the successful transition from a B2B life sciences service provider to a consumer-centric longevity and wellness brand.
⚠ அபாய எச்சரிக்கைகள்
Zero promoter holding (0.0%)
Execution risk in a new consumer-facing business segment
👀 கவனிக்க வேண்டியவை
Monitor the sustainability of the new revenue streams and the execution timeline for the 'Biohacking' and 'Nutraceutical' product launches. Investors should also watch for any updates on the 0% promoter holding situation mentioned in the financial context.
TAKE Solutions Proposes Sunil Patra as MD for 5 Years with ₹5 Lakh Annual Remuneration
TAKE Solutions is seeking shareholder approval via postal ballot for the appointment of Mr. Sunil Patra as Managing Director for a five-year term (May 2026 to May 2031). The proposed remuneration is capped at ₹5,00,000 per annum, which is notably low for a listed company with a ₹328 Cr market cap. This leadership transition occurs as the company reports 0.0% promoter holding and a negative operating margin of -3.5%. Shareholders must cast their votes between July 16 and August 14, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company is formalizing the appointment and compensation structure for its new Managing Director through a shareholder vote.
ஏன் இது முக்கியம்Leadership stability is critical given the company's recent financial volatility and the total exit of promoters; however, the very low remuneration level may raise questions regarding executive incentives.
Proposed MD Remuneration: ₹5,00,000 per annumAppointment Duration: 5 yearsPromoter Holding: 0.0%TTM Operating Profit Margin: -3.5%Market Capitalization: ₹328 கோடி
📅 குறுகிய காலம்The stock is likely to remain neutral in the short term as this is a procedural voting requirement for a previously announced leadership change.
📈 நீண்ட காலம்The long-term outlook depends on the new MD's ability to scale the Navitas brand and stabilize margins at the targeted 19-20% level despite zero promoter backing.
⚠ அபாய எச்சரிக்கைகள்
Zero promoter holding
Exceptionally low executive remuneration
Negative operating margins
High dependence on the US market
👀 கவனிக்க வேண்டியவை
Investors should monitor the voting results on August 14, 2026, and look for the new MD's strategic roadmap to improve the current -3.5% operating margin and address the lack of promoter skin in the game.
TAKE Solutions Reports FY26 Turnaround with ₹2.72 Cr Profit; Auditor Issues Qualified Opinion
TAKE Solutions has resubmitted its audited financial results for FY26 to comply with SEBI's reporting format for audit qualifications. The company reported a significant turnaround with a standalone net profit of ₹271.91 Lakhs, compared to a massive loss of ₹6,973.56 Lakhs in FY25. However, the auditor issued a qualified opinion regarding the recoverability of ₹875.80 Lakhs in disputed income tax assets, a repetitive concern since 2023. The company has used divestment proceeds to clear immediate debt and is now focusing on business diversification.
முக்கிய அம்சங்கள்
Reported a standalone net profit of ₹271.91 Lakhs in FY26 vs a net loss of ₹6,973.56 Lakhs in FY25.Auditor issued a qualified opinion on ₹875.80 Lakhs of income tax assets pending since FY 2020-21.Total income for the standalone entity stood at ₹661.75 Lakhs for the financial year ended March 31, 2026.Company has substantially cleared immediate statutory and debt obligations using proceeds from the Ecron Acunova divestment.Management is pursuing business diversification and non-cash M&A transactions to sustain the business as a going concern.
👀 கவனிக்க வேண்டியவை
Investors should weigh the positive turnaround in profitability against the persistent audit qualification regarding tax assets. Monitor the company's progress in its new business diversification strategy and the resolution of long-standing tax disputes.
Take Solutions Shareholders Approve Name Change and New Auditor with 99.9% Majority
Take Solutions Limited has successfully passed four key resolutions via postal ballot with overwhelming shareholder support of over 99.9%. Major approvals include a change in the company's name and the appointment of M/s. A. Raghavendra Rao & Associates as Statutory Auditors to fill a casual vacancy. Furthermore, shareholders approved significant alterations to the Memorandum of Association (MOA), including the insertion of new object clauses. These changes indicate a potential strategic pivot or rebranding for the organization.
முக்கிய அம்சங்கள்
Resolution for company name change and MOA/AOA alterations passed with 99.99% majority (2,45,16,599 votes).Appointment of M/s. A. Raghavendra Rao & Associates as Statutory Auditors approved by 99.99% of voting members.Alteration of the MOA Object Clause to include new business activities received 99.98% approval.All resolutions were officially deemed passed on June 16, 2026, following the conclusion of the remote e-voting process.
👀 கவனிக்க வேண்டியவை
Investors should monitor the specific details of the name change and the new object clauses to understand the company's future business direction. While the auditor change is to fill a casual vacancy, it is important to ensure continuity in financial reporting quality.
TAKE Solutions FY26 Total Income Surges 496% to ₹6,087 Lakhs; Returns to Profitability
TAKE Solutions reported a massive operational turnaround in FY26, with consolidated total income growing 495.68% YoY to ₹6,087.26 Lakhs. The company achieved a net profit of ₹1,084.91 Lakhs for the full year, resulting in an EPS of ₹0.74, compared to significant losses in the previous fiscal year. Revenue from operations resumed strongly at ₹5,418.53 Lakhs after a nil base in FY25, driven by a strategic shift toward AI-driven healthcare and digital wellness platforms. The performance was heavily weighted toward Q4 FY26, which contributed ₹5,937.02 Lakhs to the total income, indicating a sharp recovery in the final quarter.
முக்கிய அம்சங்கள்
Consolidated Total Income grew 495.68% YoY to ₹6,087.26 Lakhs in FY26.Reported a consolidated Net Profit of ₹1,084.91 Lakhs in FY26 with an EPS of ₹0.74.Revenue from operations resumed at ₹5,418.53 Lakhs versus nil in the previous financial year.Q4 FY26 income surged 3400% YoY to ₹5,937.02 Lakhs, showing massive sequential momentum.Standalone performance turned around from a loss of ₹6,973.56 Lakhs in FY25 to a profit of ₹271.91 Lakhs in FY26.
👀 கவனிக்க வேண்டியவை
Investors should view this as a significant turnaround story, particularly the resumption of operational revenue and the return to profitability. Monitor the sustainability of the Q4 growth momentum and the execution of the new ₹5 crore Innovation Fund for AI-driven healthcare.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
TAKE Solutions Appoints Sunil Patra as Managing Director and CFO for 5-Year Term
TAKE Solutions has announced a significant leadership transition by appointing Mr. Sunil Patra as both Managing Director and Chief Financial Officer, effective May 19, 2026. The MD appointment is for a five-year term, subject to shareholder approval within the next three months or at the next general meeting. Mr. Patra's background includes experience in customer service operations, business coordination, and financial management. This move consolidates two critical executive functions under a single individual, which may streamline decision-making processes.
முக்கிய அம்சங்கள்
Appointment of Mr. Sunil Patra as Managing Director for a 5-year term starting May 19, 2026Simultaneous appointment of Mr. Sunil Patra as the Chief Financial Officer (CFO)Shareholder approval required within 3 months or at the next general meeting per SEBI regulationsConfirmation received that the appointee is not debarred by SEBI or any other regulatory authority
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's performance under this consolidated leadership and watch for the upcoming shareholder vote to ratify the appointment. The dual role of MD and CFO is unusual and warrants attention regarding corporate governance checks and balances.
Take Solutions Limited Issues Postal Ballot Notice for Name Change and Object Clause Alteration
Take Solutions Limited has issued a Postal Ballot notice seeking shareholder approval for several key changes. The company proposes to shorten its name from 'TAKE SOLUTIONS LIMITED' to 'TAKE LIMITED'. Additionally, it seeks to appoint M/s. A. Raghavendra Rao & Associates as Statutory Auditors to fill a casual vacancy caused by the resignation of M/s. Venkat and Rangaa LLP. Crucially, the company is expanding its Main Objects clause to include technology-driven healthcare solutions, digital health platforms, and pharmaceutical manufacturing and research.
முக்கிய அம்சங்கள்
Proposes name change from 'TAKE SOLUTIONS LIMITED' to 'TAKE LIMITED' subject to MCA approval.E-voting period is scheduled to commence on May 18, 2026, and conclude on June 16, 2026.Appoints M/s. A. Raghavendra Rao & Associates as Statutory Auditors following the resignation of M/s. Venkat and Rangaa LLP.Alters the Main Object Clause of the MOA to insert new clauses (4, 5, 6, and 7) focusing on digital healthcare, diagnostic services, and pharmaceutical manufacturing.
👀 கவனிக்க வேண்டியவை
Investors should monitor the voting results after June 16, 2026, and watch for strategic execution details regarding the company's expanded focus into digital healthcare and pharmaceutical manufacturing.
Take Solutions to Rebrand as Take Limited and Expand into Healthcare Tech and Diagnostics
Take Solutions Limited has announced a strategic pivot by proposing a name change to 'Take Limited' and significantly expanding its business objects. The company intends to enter high-growth sectors including healthcare technology, digital health solutions, diagnostics, and biotechnology. To facilitate this, the board has approved a new Memorandum of Association and appointed M/s. A. Raghavendra Rao & Associates as Statutory Auditors to fill a casual vacancy. Shareholders will vote on these proposals via a postal ballot process ending June 16, 2026.
முக்கிய அம்சங்கள்
Proposed name change from 'TAKE SOLUTIONS LIMITED' to 'TAKE LIMITED' subject to MCA and member approval.Expansion of business objects to include healthcare technology, digital health, diagnostics, pharmaceuticals, and biotechnology.Appointment of M/s. A. Raghavendra Rao & Associates as Statutory Auditors to fill a casual vacancy.Postal ballot e-voting period scheduled from May 18, 2026, to June 16, 2026, with a cut-off date of May 08, 2026.Adoption of a new set of Memorandum of Association (MOA) to align with the Companies Act, 2013.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's transition into the healthcare and diagnostic sectors for potential revenue diversification. Additionally, shareholders should investigate the reasons behind the 'casual vacancy' of the previous statutory auditor before casting their votes.
Take Solutions Enters Longevity & Anti-Ageing Market Targeting $67B Global Opportunity
Take Solutions has announced a strategic entry into the longevity and anti-ageing sector, leveraging its clinical research and life sciences expertise. The company aims to capture a share of the global longevity market, projected to reach $67.03 billion by 2035 with a 9.41% CAGR. In India, the anti-aging supplements market is expected to grow from $168.6 million in 2025 to $341.4 million by 2033. The strategy includes developing science-backed nutraceuticals and digital biohacking tools to diversify revenue streams.
முக்கிய அம்சங்கள்
Targeting global longevity market valued at $27.61 billion in 2025, growing at 9.41% CAGRFocus on India's anti-aging supplements market, projected to reach $341.4 million by 2033India's anti-aging services market expected to grow to $1,059.6 million by 2035Strategy involves a dual model of nutraceutical products and predictive digital health toolsLeveraging existing regulatory and clinical research capabilities to ensure product credibility
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution timeline for product launches and the impact on margins, as this represents a shift toward consumer-facing healthcare. The stock may see positive sentiment due to the high-growth nature of the longevity and biohacking sectors.
TAKE Solutions Appoints New Statutory Auditors Following Resignation of Previous Firm
TAKE Solutions Limited has appointed M/s. A. Raghavendra Rao & Associates as Statutory Auditors to fill a casual vacancy. This follows the resignation of the previous auditors, M/s. Venkat and Rangaa LLP, effective March 26, 2026. The new firm brings nearly 40 years of experience in audit, taxation, and advisory services across multiple sectors including IT and healthcare. The appointment is subject to shareholder approval as per SEBI regulations.
முக்கிய அம்சங்கள்
Appointment of M/s. A. Raghavendra Rao & Associates as Statutory Auditors effective March 26, 2026.The change follows the resignation of the outgoing auditor, M/s. Venkat and Rangaa LLP.The new auditing firm was established in 1986 and has nearly 40 years of experience in corporate and government audits.The Board meeting approving the appointment was held on March 26, 2026, between 06:30 PM and 07:00 PM.
👀 கவனிக்க வேண்டியவை
Investors should monitor for the specific reasons behind the previous auditor's resignation to ensure there are no governance or accounting red flags. Maintain a cautious stance until the next audited financial results are published under the new firm.
Statutory Auditor Venkat and Rangaa LLP Resigns from Take Solutions Due to Fee Constraints
Take Solutions Limited has announced the resignation of its statutory auditor, M/s. Venkat and Rangaa LLP, effective March 25, 2026. The auditor cited that the audit fees were not commensurate with the size and complexity of the business and the reporting requirements. Notably, the auditor resigned just 50 days after their appointment on February 3, 2026. The firm had recently submitted the Limited Review Report for the quarter ended December 2025 on February 14, 2026.
முக்கிய அம்சங்கள்
M/s. Venkat and Rangaa LLP resigned as Statutory Auditor effective March 25, 2026.The auditor was appointed on February 3, 2026, resulting in an exceptionally short tenure of less than two months.Reason for resignation: Audit remuneration was deemed insufficient relative to the company's business complexity and statutory scope.The auditor confirmed there are no other material reasons for the resignation beyond the fee constraints.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as frequent or sudden auditor changes can sometimes signal underlying governance or financial reporting disagreements. Monitor the company's next appointment and the transition process closely.
TAKE Solutions Launches Take.Health AI Platform Targeting $197B Healthcare Market
TAKE Solutions has launched Take.Health, an AI-driven digital health companion designed to capitalize on India's $197 billion preventive healthcare opportunity. The platform utilizes an asset-light, subscription-based model to provide personalized health insights, lab report analysis, and chronic condition tracking for retail and enterprise segments. This strategic move aims to create recurring revenue streams by leveraging India's base of over 600 million smartphone users. The initiative marks a significant pivot for the company into the high-growth digital health and AI analytics space.
முக்கிய அம்சங்கள்
Targets India's preventive healthcare market projected to reach $197 billion by 2030.Platform features AI-powered lab analysis, predictive risk identification, and condition-specific tracking for diabetes and hypertension.Business model focuses on scalable, recurring revenue through subscriptions and data-led services.Leverages India's digital adoption base of over 600 million smartphone users for rapid scaling.Positions the company to participate in the broader $370 billion Indian healthcare sector through a technology-first approach.
👀 கவனிக்க வேண்டியவை
Investors should monitor user adoption metrics and subscription growth for Take.Health as it represents a high-margin digital pivot. Watch for partnership announcements with diagnostics and insurance providers which could further validate the platform's ecosystem value.
TAKE Solutions Approves Shifting Registered Office and Appoints New Statutory Auditors
TAKE Solutions held an Extraordinary General Meeting (EOGM) on March 7, 2026, to approve several key governance and strategic changes. Shareholders voted to regularize the appointments of two Non-Executive Directors and approved M/s. Venkat and Rangaa LLP as the new Statutory Auditors following a casual vacancy. A significant special resolution was passed to shift the company's Registered Office from Tamil Nadu to Maharashtra. These moves coincide with the company's stated strategic transformation toward AI-driven healthcare and scalable technology platforms.
முக்கிய அம்சங்கள்
Approved the appointment of M/s. Venkat and Rangaa LLP as Statutory Auditors following the resignation of M/s. Sundar Srini & Sridhar.Passed a special resolution to shift the Registered Office from Tamil Nadu to Maharashtra.Regularized the appointments of Mr. Parmeshvar Dhangare and Mr. Vilas Munis as Non-Executive Directors.Company reported a total of 66,526 members as of the February 28, 2026, cut-off date.Management highlighted a strategic pivot toward AI-driven healthcare, diagnostics, and preventive care.
👀 கவனிக்க வேண்டியவை
Investors should monitor the transition to the new statutory auditors and the relocation to Maharashtra for any operational disruptions. The strategic shift toward AI-driven healthcare is a long-term play that requires tracking for actual revenue execution.
TAKE Solutions EOGM: Shifting Office to Maharashtra and New Auditor Appointment
TAKE Solutions held an Extra Ordinary General Meeting on March 7, 2026, to approve several key governance and operational changes. Shareholders voted on the regularization of two Non-Executive Directors and the appointment of M/s. Venkat and Rangaa LLP as Statutory Auditors following a casual vacancy. A significant special resolution was proposed to shift the company's registered office from Tamil Nadu to Maharashtra. The management also emphasized a strategic pivot toward AI-driven healthcare and diagnostics platforms.
முக்கிய அம்சங்கள்
Approval for shifting the Registered Office from Tamil Nadu to Maharashtra via a Special Resolution.Appointment of M/s. Venkat and Rangaa LLP as Statutory Auditors to fill the vacancy caused by the resignation of M/s. Sundar Srini & Sridhar.Regularization of Mr. Parmeshvar Dhangare and Mr. Vilas Munis as Non-Executive Non-Independent Directors.The meeting was attended by 38 members out of a total shareholder base of 66,526 as of February 28, 2026.Strategic focus reaffirmed on building scalable technology-led platforms in AI-driven healthcare and preventive care.
👀 கவனிக்க வேண்டியவை
Investors should monitor the transition to the new registered office and any further disclosures regarding the auditor's resignation. The company's shift toward AI-driven healthcare is a long-term strategic move that requires tracking for execution milestones.
TAKE Solutions Integrates Anthropic's Claude AI to Target $370B Healthcare Sector
TAKE Solutions has announced a strategic integration of Anthropic’s Claude AI to enhance its healthcare technology stack. This move specifically targets the $370 billion healthcare sector by powering platforms like the 'One Minute Clinic' and a 'Unified AI Marketplace'. The initiative focuses on transitioning from reactive treatment to predictive and preventive care models using advanced clinical decision intelligence. By leveraging these AI capabilities, the company aims to improve operational efficiency and scale its services for global healthcare networks and pharmaceutical companies.
முக்கிய அம்சங்கள்
Strategic integration of Anthropic's Claude AI to drive dominance in the $370B global healthcare market.Enhancement of the 'One Minute Clinic' initiative for rapid health assessments and intelligent report generation.Development of a Unified AI Marketplace for hospitals, diagnostic centers, and pharmaceutical providers.Focus on predictive healthcare management to identify early health risks and enable proactive care.
👀 கவனிக்க வேண்டியவை
Investors should view this as a significant technological upgrade that positions the company in the high-growth AI-healthcare segment. Monitor the company's upcoming quarterly results for signs of revenue traction from these newly enhanced AI platforms.
TAKE Solutions to Build Unified AI Platform for $370B Healthcare Ecosystem
TAKE Solutions has announced a strategic initiative to develop a Scalable Unified AI Platform, targeting India's $370 billion healthcare sector and a $197 billion preventive healthcare opportunity. The platform will act as a digital infrastructure layer and marketplace, enabling hospitals and labs to deploy AI for diagnostics, clinical trials, and hospital workflows. This move aligns with the IndiaAI Mission and positions the company to capture growth in the global AI healthcare market, which is projected to exceed $180 billion by 2030. The initiative marks a significant pivot toward high-growth digital health infrastructure.
முக்கிய அம்சங்கள்
Developing a Unified AI Platform to address the $370 billion Indian healthcare ecosystem.Targeting a $197 billion preventive healthcare opportunity through democratized AI access.Platform to serve as a Healthcare AI Marketplace for diagnostics, clinical trials, and hospital workflows.Strategic alignment with the IndiaAI Mission and the global AI healthcare market projected to surpass $180 billion by 2030.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to onboard healthcare providers and the subsequent impact on revenue growth from this digital platform. While the strategic direction is positive, execution and monetization within the competitive AI space will be critical factors to watch.
Take Solutions Reports Q3 Profit of ₹1.11 Cr; Auditors Raise Going Concern Doubts
Take Solutions reported a standalone net profit of ₹110.96 Lakhs for Q3 FY26, though this was driven entirely by other income as revenue from operations remained at zero. The company's auditors have issued a qualified opinion, highlighting material uncertainty regarding the firm's ability to continue as a going concern due to significant past losses and unpaid statutory dues. Management is currently exploring non-cash M&A opportunities to diversify operations following the divestment of its major subsidiary. Additionally, the board has rejected a promoter's request for reclassification to the public category citing procedural gaps.
முக்கிய அம்சங்கள்
Revenue from operations stood at ₹0.00 for the quarter, with total income of ₹146.14 Lakhs derived from other sources.Auditors flagged ₹883.2 Lakhs in tax assets and ₹516.4 Lakhs in indirect tax credits with uncertain recoverability.Company faces contingent liabilities of ₹1,080.3 Lakhs related to direct tax litigations pending before various forums.Net worth remains significantly impacted by a ₹6,973.60 Lakhs loss in the previous financial year following the Ecron Acunova divestment.The Board declined Mr. Srinivasan HR's request to move from 'Promoter' to 'Public' category due to pending procedural requirements.
👀 கவனிக்க வேண்டியவை
Investors should remain highly cautious as the auditor's 'going concern' warning and lack of operational revenue indicate extreme financial risk. The stock is speculative until the company successfully executes its proposed M&A strategy or restarts core business operations.
Take Solutions to Hold EOGM for Auditor Appointment and Office Shift to Maharashtra
Take Solutions Limited has scheduled an Extraordinary General Meeting (EOGM) for March 07, 2026, to seek shareholder approval for several significant corporate changes. Key resolutions include the appointment of M/s. Venkat and Rangaa LLP as Statutory Auditors following the resignation of the previous auditors. The company also proposes shifting its registered office from Tamil Nadu to Maharashtra, which requires a special resolution. Additionally, shareholders will vote on the regularization of two Non-Executive Directors, Mr. Parmeshvar Dhangare and Mr. Vilas Munis.
முக்கிய அம்சங்கள்
EOGM scheduled for March 07, 2026, to be held via Video Conferencing/Other Audio-Visual Means.Proposed appointment of M/s. Venkat and Rangaa LLP as Statutory Auditors to fill a casual vacancy.Special resolution to shift the Registered Office from Chennai, Tamil Nadu, to the State of Maharashtra.Regularization of Mr. Parmeshvar Dhangare and Mr. Vilas Munis as Non-Executive Non-Independent Directors.Remote e-voting period is set from March 04 to March 06, 2026, with a cut-off date of February 28, 2026.
👀 கவனிக்க வேண்டியவை
Investors should monitor the rationale behind the auditor's resignation and the strategic purpose of shifting the registered office to Maharashtra. Shareholders eligible as of February 28, 2026, should participate in the e-voting process to voice their stance on these governance changes.
Take Solutions to Shift Office to Maharashtra, Appoints New Auditor and Reviews Promoter Exit
Take Solutions has announced a major structural shift, moving its registered office from Tamil Nadu to Maharashtra. The board has appointed M/s. Venkat and Rangaa LLP as the new Statutory Auditor to fill a casual vacancy following the previous auditor's resignation. Crucially, the board is reviewing a request from promoter Mr. Srinivasan H R to be reclassified as a public shareholder, with a follow-up meeting scheduled for February 14, 2026. Additionally, the company is progressing with an AI-driven Diagnostic & Preventive Health Care Platform as part of its long-term strategy.
முக்கிய அம்சங்கள்
Proposed shifting of registered office from Tamil Nadu to Maharashtra subject to shareholder approval.Appointment of M/s. Venkat and Rangaa LLP as Statutory Auditors following the resignation of M/s Sundar Srini & Sridhar.Promoter Mr. Srinivasan H R has formally requested reclassification from 'Promoter' to 'Public' category.Extra Ordinary General Meeting (EOGM) scheduled for March 7, 2026, for member approvals.Board reviewed progress on an advanced AI-driven Diagnostic & Preventive Health Care Platform.
👀 கவனிக்க வேண்டியவை
Investors should closely monitor the February 14 board meeting regarding the promoter's reclassification request, as this often signals a change in management control or potential exit. The change in statutory auditors also necessitates a review of the company's recent financial disclosures for any underlying issues.
Take Solutions Appoints New Director, Shifts Registered Office, and Reviews AI Platform
Take Solutions has announced a series of corporate changes, including the appointment of Mr. Vilas Munis as a Non-Executive Director and the shifting of its registered office from Tamil Nadu to Maharashtra. The company is also filling a statutory auditor vacancy following a resignation and has scheduled an EOGM for March 7, 2026, for shareholder approvals. Significantly, the board is reviewing a request from promoter Mr. Srinivasan H R to be reclassified as a public shareholder, with a decision expected on February 14, 2026. Additionally, the company is progressing with its long-term roadmap for an AI-driven Diagnostic & Preventive Health Care Platform.
முக்கிய அம்சங்கள்
Appointment of Mr. Vilas Munis as Additional Non-Executive Director effective February 11, 2026.Proposed shifting of the Registered Office from Tamil Nadu to Maharashtra subject to shareholder and MCA approval.M/s. Venkat and Rangaa LLP appointed as Statutory Auditors to fill a casual vacancy caused by a resignation.Promoter Mr. Srinivasan H R has requested reclassification to the 'Public' category, to be reviewed on February 14, 2026.Extra Ordinary General Meeting (EOGM) scheduled for March 7, 2026, with e-voting starting March 4, 2026.
👀 கவனிக்க வேண்டியவை
Investors should closely monitor the outcome of the February 14 board meeting regarding promoter reclassification and the reasons behind the auditor change. The shift in registered office and management changes suggest a significant corporate transition that requires a cautious approach.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
